NJXB(SH:600682) Xin Lang Cai Jing·2025-11-14 01:55Core Viewpoint - Nanjing Xinbai's stock price has shown significant volatility, with a year-to-date increase of 28.96% and a recent decline of 2.00% on November 14, 2023, indicating potential market fluctuations and investor sentiment shifts [1][2]. Financial Performance - For the period from January to September 2025, Nanjing Xinbai reported a revenue of 4.773 billion yuan, a year-on-year decrease of 2.02%, and a net profit attributable to shareholders of 212 million yuan, down 4.14% compared to the previous year [3]. - The company has cumulatively distributed 1.117 billion yuan in dividends since its A-share listing, with 88.3827 million yuan distributed over the last three years [4]. Shareholder and Market Activity - As of September 30, 2025, the number of shareholders increased by 13.85% to 45,700, while the average circulating shares per person decreased by 12.17% to 25,485 shares [3]. - Nanjing Xinbai has appeared on the "Dragon and Tiger List" twice this year, with the most recent instance on July 24, 2023, where it recorded a net buy of -17.0404 million yuan [2]. Business Overview - Nanjing Xinbai, established on May 14, 1991, and listed on October 18, 1993, operates in various sectors including retail, healthcare, and elder care services. Its main revenue sources are health and elder care (36.97%), pharmaceutical manufacturing (23.74%), and medical services (15.26%) [2]. - The company is categorized under the comprehensive industry sector and is associated with concepts such as stem cells, gene sequencing, private hospitals, new retail, and undervalued stocks [2].